Summary The Asia-Pacific region is home to more than half of the global population and
accounted for 62· 6% of global deaths due to liver diseases in 2015. 54· 3% of global deaths …

The treatment of chronic hepatitis C virus (HCV) infection has the potential to change
significantly over the next few years as therapeutic regimens are rapidly evolving. However …

This Review presents current epidemiological trends of the most common liver diseases in
Asia–Pacific countries. Hepatitis B virus (HBV) remains the primary cause of cirrhosis; …

Background. The study aimed to evaluate the risk of hepatitis C virus (HCV) infection on
hepatic and extrahepatic deaths. Methods. A cohort of 23 820 adults aged 30–65 years old …

Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of
substantial morbidity and mortality in the future. The complexity and uncertainty related to …

Background: The hepatitis C pandemic has been systematically studied and characterized
in North America and Europe, but this important public health problem has not received …

The pace of therapeutic advances in the treatment of chronic viral hepatitis, such as hepatitis
B and hepatitis C, has accelerated significantly in the past decade. The hepatitis B virus …

There is a paucity of community‐based epidemiological data on nonalcoholic fatty liver
(NAFL) among nonaffluent populations in developing countries. Available studies are …

Hepatitis C virus (HCV) affects 130-210 million people worldwide and is one of the major
risk factors for hepatocellular carcinoma. Globally, at least one third of hepatocellular …

Symptomatic acute hepatitis C occurs in only about 15% of patients who are infected with
hepatitis C virus (HCV). Acute hepatitis C is most often diagnosed in the setting of post …